Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 08/04/2013 19453_de.jpg

    HI-Virus maturation by budding

    The Heidelberg virologist Hans-Georg Kräusslich and his team are exploring the molecular architecture and morphogenesis of the HI-Virus and the processes occurring at the plasma membrane of the host cell that lead to the release of new viruses and new infections. The budding and maturation processes of HIV particles and the lipid composition of their envelope could be used as targets for the development of new drugs to combat AIDS.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hi-virus-maturation-by-budding
  • Article - 19/04/2010 The microscope image shows six spherical structures closely attached to each other.<br />

    Trying to get a virus to reveal its tricks

    The Thogoto virus is an exotic virus that presents virtually no danger to humans. A group of virologists led by Prof. Dr. Georg Kochs at the Freiburg University Medical Centre are using the virus as model system for its particular suitability in certain experiments. The group is investigating how the virus evades the antiviral defence of the infected host.

    https://www.gesundheitsindustrie-bw.de/en/article/news/trying-to-get-a-virus-to-reveal-its-tricks
  • Press release - 29/06/2009

    New electron microscopy images reveal the assembly of HIV

    Scientists at the European Molecular Biology Laboratory (EMBL) and the University Clinic Heidelberg, Germany, have produced a three-dimensional reconstruction of HIV (Human Immunodeficiency Virus), which shows the structure of the immature form of the virus at unprecedented detail. Immature HIV is a precursor of the infectious virus, which can cause AIDS. The study, published in the 22-26 June online edition of PNAS, describes how the protein…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-electron-microscopy-images-reveal-the-assembly-of-hiv
  • Article - 02/07/2009 HCMV has been detected in a renal artery organ model. The electron microscope image clearly shows the spiky spherical pathogen.

    A virus that hides while it waits for an opportunity to replicate

    Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
  • Article - 15/09/2017 Teaser_ZIKA_Virus_Jarasch.jpg

    Zika virus infections and their consequences

    Infections caused by mosquito-borne Zika viruses during pregnancy can lead to severe brain defects in babies. The European Union has provided funding of around ten million euros for an international research programme on Zika virus infections in which the University Hospital of Heidelberg plays a key role.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zika-virus-infections-and-their-consequences
  • COVIC-19 clinical trial - 07/04/2022 Schematic showing how the clinical trial will be performed.

    Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity

    Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.

    https://www.gesundheitsindustrie-bw.de/en/article/news/convalescent-plasma-covid-19-therapy-clinical-trial-should-bring-clarity
  • Press release - 24/07/2012 17760_de.jpg

    Tailor-made viruses for enhanced cancer therapy

    Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, as they can also infect normal cells - without doing any harm to them - a large portion of viruses is lost during therapy. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-viruses-for-enhanced-cancer-therapy
  • Press release - 17/02/2021

    A new piece of the HIV infection puzzle explored

    Researchers from EMBL and Heidelberg University Hospital combine high-resolution imaging to observe the infection process in cell nuclei, opening the door for new therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-piece-hiv-infection-puzzle-explored
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Macrophages interacting with cytomegaloviruses - 22/02/2022 Graphik_CMV_Makrophagen_Teaser.jpg

    Cytomegaloviruses subvert macrophage identity

    Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
  • Press release - 23/12/2009 Portrait of Prof. Dr. Frank Kirchhoff

    The spread of HIV: optimal adaptation to the human host

    A new study led by the virologist and Leibniz Award winner Frank Kirchhoff from Ulm might be about to provide an explanation as to why only one of several independent transmissions of simian immunodeficiency viruses (SIV) from chimpanzees to humans led to the global AIDS pandemic. The researchers now hope that these new findings will contribute to the search for new strategies to prevent the further spread of AIDS viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-spread-of-hiv-optimal-adaptation-to-the-human-host
  • Article - 01/03/2008 Hepatitis B virus (Figure: Roche)

    New active substance against hepatitis B

    Scientists at the University Hospital in Heidelberg have discovered a hepatitis B virus peptide that can prevent viral infections in a mouse model. A team led by Professor Stephan Urban is developing a virus blocker against hepatitis B infections. Despite vaccinations every year about 750000 people die from the consequences of hepatitis B infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-active-substance-against-hepatitis-b
  • Press release - 17/07/2012 AnDiaTec Logo

    Schmallenberg virus: Identifying infected cows and sheep faster

    The world's first commercial detection method for the Schmallenberg virus is now available for all laboratories. Kornwestheim-based AnDiaTec GmbH & Co. KG, specialists in detection methods for pathogens in the veterinary field, has just received approval for its product from the Friedrich-Löffler-Institut under the German Ordinance on Working with Animal Pathogens (Tierseuchengesetz). The virus, which has led, among other things, to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/schmallenberg-virus-identifying-infected-cows-and-sheep-faster
  • Article - 15/12/2014 22544_de.jpg

    From HIV structure to new AIDS therapies

    The building blocks of the viral protein capsid are rearranged as HI viruses mature into infectious AIDS-causing agents. Researchers from Heidelberg have made these structural changes visible on the molecular level. The findings could potentially be used for developing much-needed new AIDS therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/news/from-hiv-structure-to-new-aids-therapies
  • Article - 12/03/2012 16587_de.jpg

    Q-bios provides client-specific biotechnology services

    Q-bios GmbH, a spin-off from the Mannheim University of Applied Sciences, is a biotechnology company that provides services related to the production and purification of diagnostic and therapeutic proteins as well as the development and amplification of suitable cell lines. The company offers its services, which are based on state-of-the-art technologies, to clients from the biotechnology, diagnostic and pharmaceutical industries.

    https://www.gesundheitsindustrie-bw.de/en/article/news/q-bios-provides-client-specific-biotechnology-services
  • Article - 20/12/2007

    Viruses are the major cause of myocardial diseases

    About 500000 people in Germany suffer from dilatative cardiomyopathy DCM. Viral infections are the major cause of this myocardial disease. Its molecular and cellular mechanisms are being investigated in a transregional SFB project at the University of Tübingen.

    https://www.gesundheitsindustrie-bw.de/en/article/news/viruses-are-the-major-cause-of-myocardial-diseases
  • Article - 09/07/2009 An RNA tumor virus budding from the surface of a mouse sarcoma cell and a virus already released from the cell. Electron micrograph (Source: Cell and Tumor Biology, German Cancer research Center, Heidelberg)

    Four Nobel Prizes for a chicken virus

    The Rous sarcoma virus (RSV) was the starting point of the discovery that cancer can be brought on by infections. The enzyme “reverse transcriptase”, which led to a rethinking and technological revolution in the field of molecular biology, was discovered in this retrovirus along with oncogenes that led to a completely new concept of cancer development in molecular genetics and eventually to the development of a new generation of cancer…

    https://www.gesundheitsindustrie-bw.de/en/article/news/four-nobel-prizes-for-a-chicken-virus
  • Article - 29/11/2010 12175_de.jpg

    Against chronic liver inflammation and liver cancer

    Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.

    https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Press release - 16/11/2009 10118_de.jpg

    No-Entry Zones for AIDS Virus

    The AIDS virus (HIV) inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-entry-zones-for-aids-virus
  • Article - 24/11/2015 The researchers from Tübingen were able to decipher in detail the site where the JC polyomavirus binds to the host cell. The yellow molecule structure shows the sugar residues on the surface of the host cell encased in the binding pocket of the viral protein.

    Researchers from Tübingen set out to thwart viral survival strategies

    Around two thirds of people carry the JC polyomavirus, a normally harmless virus that, in immunocompromised patients, can evade the body’s defences and cause a fatal brain infection. An international research network has now found a way to activate the immune system and attack the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/researchers-from-tuebingen-set-out-to-thwart-viral-survival-strategies
  • Press release - 01/11/2010 12799_de.jpg

    A virus discloses its secret: how does JCV infect body cells?

    Viruses can infect cells when they detect specific attachment sites on the cells’ surface. An international group of researchers, including biochemists from Tübingen, have now discovered the molecular mechanism by which the JCV polyomavirus attaches to these receptors. The researchers deciphered the atomic structure of the virus and for the first time ever were able to prevent the virus from attaching to the host cell and causing infection.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/a-virus-discloses-its-secret-how-does-jcv-infect-body-cells
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
  • Press release - 08/09/2010

    Prevention and Treatment of Chronic Hepatitis C

    GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-and-treatment-of-chronic-hepatitis-c
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power

Page 1 / 8

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search